Obesity Surgery

, Volume 26, Issue 4, pp 749–756 | Cite as

Prediction of Diabetes Remission in Morbidly Obese Patients After Roux-en-Y Gastric Bypass

  • Ji Yeon Park
  • Yong Jin Kim
Original Contributions



Morbidly obese patients with type 2 diabetes have shown significant improvement in glycemic control after Roux-en-Y gastric bypass (RYGB). This study aimed to elucidate the predictors of diabetes remission.


A retrospective review of a prospectively established database identified 134 type 2 diabetes patients who underwent laparoscopic RYGB between January 2011 and February 2014. Partial and complete remission of diabetes was defined as glycated hemoglobin (HbA1c) level <6.5 and <6.0 %, respectively, without the use of antidiabetic medication. Pre- and postoperative clinical outcomes were compared between the remission and non-remission groups to identify the predictors of partial or complete remission of diabetes.


The mean duration of diabetes and preoperative HbA1c level were 4.6 years and 8.0 %, respectively. The body mass index (BMI) of the enrolled patients decreased from 37.9 to 28.8 kg/m2 during the mean follow-up of 12.3 months; 61.8 % of the patients achieved partial or complete remission of diabetes. Multivariate analysis revealed that age at operation (odds ratio [OR] = 0.880; 95 % confidence interval [CI] 0.807–0.960), HbA1c level (OR = 0.527; 95 % CI 0.325–0.854), and C-peptide level (OR = 1.463; 95 % CI 1.054–2.029) in the preoperative laboratory study, and the percentage of total weight loss (%TWL) (OR = 1.186; 95 % CI 1.072–1.313) after RYGB were the independent predictors of partial or complete diabetes remission.


The predictive factors for diabetes remission after RYGB include age at operation, HbA1c and C-peptide levels, and the %TWL after surgery.


Morbid obesity Roux-en-Y gastric bypass Type 2 diabetes Diabetes remission 



Min Ju Soh and Suyeon Park contributed to this study as a research coordinator and a statistician, respectively. This research was supported by the Soonchunhyang University Research Fund.

Conflict of Interest

The authors declare that they have no competing interests.

Informed Consent

The need for patient informed consent for this retrospective study was waived by the institutional review board.

Ethical Approval

This study was approved by the institutional ethics committee of Soonchunhyang University Seoul Hospital and has been performed in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Jeon JY, Kim DJ, Ko SH, et al. Current status of glycemic control of patients with diabetes in Korea: the fifth Korea national health and nutrition examination survey. Diabet Metab J. 2014;38(3):197–203.CrossRefGoogle Scholar
  2. 2.
    Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24–32.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623–30.CrossRefPubMedGoogle Scholar
  4. 4.
    Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hutter MM, Schirmer BD, Jones DB, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg. 2011;254(3):410–20. discussion 20-2.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467–84. discussion 84-5.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20(9):1245–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35(7):1420–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Pournaras DJ, Aasheim ET, Sovik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Bi J Surg. 2012;99(1):100–3.CrossRefGoogle Scholar
  12. 12.
    Kasama K, Mui W, Lee WJ, et al. IFSO-APC consensus statements 2011. Obes Surg. 2012;22(5):677–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Association AD. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35:S11.CrossRefGoogle Scholar
  14. 14.
    Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Park JY, Song D, Kim YJ. Clinical experience of weight loss surgery in morbidly obese Korean adolescents. Yonsei Med J. 2014;55(5):1366–72.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Organization WH. The Asia-Pacific perspective: redefining obesity and its treatment: Health Communications Australia. 2000.Google Scholar
  17. 17.
    Hayes MT, Hunt LA, Foo J, et al. A model for predicting the resolution of type 2 diabetes in severely obese subjects following Roux-en Y gastric bypass surgery. Obes Surg. 2011;21(7):910–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2010;6(3):254–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Bhasker AG, Remedios C, Batra P, et al. Predictors of remission of T2DM and metabolic effects after laparoscopic Roux-en-Y Gastric bypass in obese Indian diabetics—a 5-year study. Obesity Surg. 2014.Google Scholar
  20. 20.
    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Rel Dis. 2013;9(3):379–84.CrossRefGoogle Scholar
  22. 22.
    Still CD, Wood GC, Benotti P, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabet Endocrinol. 2014;2(1):38–45.CrossRefGoogle Scholar
  23. 23.
    Campos GM, Rabl C, Peeva S, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg. 2010;14(1):15–23.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metabol. 2013;98(11):4391–9.CrossRefGoogle Scholar
  25. 25.
    Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. International journal of obesity (2005). Int J Obes. 2010;34(3):462–71.CrossRefGoogle Scholar
  26. 26.
    Salinari S, Bertuzzi A, Guidone C, et al. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects. Ann Surg. 2013;257(3):462–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Kadera BE, Lum K, Grant J, et al. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis. 2009;5(3):305–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23(1):93–102.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lee WJ, Chong K, Ser KH, et al. C-peptide predicts the remission of type 2 diabetes after bariatric surgery. Obes Surg. 2012;22(2):293–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Nannipieri M, Mari A, Anselmino M, et al. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metabol. 2011;96(9):E1372–9.CrossRefGoogle Scholar
  31. 31.
    Khanna V, Malin SK, Bena J, et al. Adults with long-duration type 2 diabetes have blunted glycemic and beta-Cell function improvements after bariatric surgery. Obesity (Silver Spring, Md). 2015.Google Scholar
  32. 32.
    DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010;6(3):249–53.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Surgery, Seoul HospitalSoonchunhyang UniversitySeoulRepublic of Korea
  2. 2.Department of SurgeryNational Cancer CenterGoyang-siRepublic of Korea

Personalised recommendations